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Cardiac surgery is the second most common cause of acute 
kidney injury (AKI) in intensive care and affects, depending 
on the definition, 8.9% to 39% of patients (1). Renal 
replacement therapy (RRT) is needed in 1–5% (1,2) of post 
cardiac surgery cases. Importantly, AKI development, even 
when serum creatinine is restored to baseline values, is 
independently associated with short and long term 
morbidity and mortality and no specific therapy is available, 
so far (3,4). Progress has been made during the last years on 
the definition of the syndrome [i.e., Kidney Disease 
Improving Global Outcome (KDIGO) criteria, (5)], on 
better understanding of its pathophysiology, and on the 
identification of earlier severity stages (6). It is now clear 
that cardiac surgery associated AKI (CSA-AKI) has a 
multifactorial origin since different pathways simultaneously 
affect renal function: patients’ pre-operative susceptibility, 
exogenous and endogenous toxins, metabolic factors, 
hemodynamic instability, ischemia/reperfusion injury, 
microembolization, neurohormonal activation, endothelial 
cells and renal epithelial cells activation, and release of 
inflammatory mediators and oxidative stress (7-9). 
Inflammation, deriving from several pathways, plays a key 
role in CSA-AKI: cardiopulmonary bypass and its contact 
activated response, aortic cross-clamp and circulatory arrest, 
tissue hypoxia, and transfusions co-act leading to a systemic 
inflammatory response syndrome (7,10-12). In light of these 
aspects, many strategical and therapeutic approaches have 
been attempted in order to limit the occurrence of AKI 
after cardiac surgery (13). Inhibitors of the 3-hydroxy-3-
methylglutaryl-coenzyme A reductase (statins) were 
introduced in clinical practice in 1987 as lipid-lowering 
agents with the specific action to decrease plasma 
cholesterol concentrations (14). It is a matter of fact that 
statins have led to significant reductions in cardiovascular 
morbidi ty  and morta l i ty  and,  in  addit ion to  the 
cardiovascular benefits, they have been found to have anti-
inflammatory effects, thus suggesting potential applications 
beyond cardiovascular diseases. Due to the potential 
properties of attenuation of inflammation and oxidative stress 
(15,16), statins have been administered as kidney protective 
agents for many years (17). Currently, experimental or 
retrospective studies have reached inconclusive and 
sometimes conflicting results (17-20). In a recent number of 
JAMA, Billings et al. published an interesting double blind 
randomized controlled trial  entit led “High-Dose 
Perioperative Atorvastatin and Acute Kidney Injury 
Following Cardiac Surgery”, designed to test short-term 
high-dose perioperative atorvastatin, in both naive and 
previously treated patients, as a protective drug against CSA-
AKI (21). Among the overall 615 recruited patients, AKI 
occurred in 20.8% in the atorvastatin group vs. 19.5% in the 
placebo group [P=0.75; relative risk (RR) 1.06 (95% CI, 0.78 
to 1.46)]. Specifically, among the patients who were naive to 
statin treatment (n=199), AKI occurred in 21.6% in the 
atorvastatin group compared with 13.4% in the placebo 
group [RR, 1.61; (95% CI, 0.86 to 3.01); P=0.15] with a 
median serum creatinine increase by 0.11 mg/dL in the 
atorvastatin group and 0.05 mg/dL in the placebo group 
[mean difference, 0.08 mg/dL (95% CI, 0.01 to 0.15 mg/dL); 
P=0.007]. Importantly, in the subgroup of patients with 
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chronic kidney disease (CKD) and naive to statin treatment, 
although limited in number (36 patients), atorvastatin was 
associated with worsening of renal outcome: acute on 
chronic kidney injury occurred in 52.9% in the atorvastatin 
group vs. 15.8% in the placebo group [RR, 3.35 (95% CI, 
1.12 to 10.05); P=0.03]. On the contrary, no significant 
differences in renal function were observed in those patients 
with CKD who were already taking a statin (P=0.59). 
Importantly, the study board recommended ending 
enrolment of patients naive to statins because of the 
increased incidence of AKI among those with CKD. The 
trial was hence interrupted for futility. Billings et al.’s study 
has important clinical implications related to statin therapy 
as clearly underlined in a related editorial (22): for patients 
not preoperatively taking statins, the treatment should not 
be initiated for “renal protection” purpose. On the other 
hand, patients chronically taking statins should not 
withdraw the therapy due to i ts  wel l-establ ished 
“cardiovascular” benefits (23). In addition, the absence of 
kidney benefits demonstrated by Billings et al.’s trial is in 
line with many large observational studies (17-20) and a 
recent Cochrane meta-analysis (14) that do not suggest 
preoperative statin for kidney protection in adults after 
surgery under CPB. In order to better understand the 
potential role of statins and many other drugs and strategies, 
in CSA-AKI, it could be useful to increase the sensitivity of 
the investigations moving back from the acute kidney 
“injury” (a late clinical condition) to the acute kidney 
“stress” (AKS). AKS has recently been suggested as a 
sub-clinical phase of AKI pathophysiology (9). In light of 
this, a number of renal biomarkers have been evaluated and 
tested to enhance the understanding and diagnosis of AKI 
and cardiorenal syndrome (24,25). Molnar et al. conducted 
a post-cardiac surgery multi-center prospective cohort study of 
625 adult patients (18). The primary study’s outcome was the 
need of acute dialysis or a doubling in serum creatinine from 
the baseline; the secondary outcome was “kidney injury” as 
identified by elevation of kidney injury biomarkers [urine 
interleukin-18 (IL-18), urine neutrophil gelatinase-associated 
lipocalin (uNGAL), urine kidney injury molecule-1 (uKIM-1), 
and plasma neutrophil gelatinase-associated lipocalin, 
(uNGAL)]. Patients were divided into statin held group (in the 
24 hours prior to surgery) and statin continued group. The 
authors showed that continuing (vs. holding) a statin prior to 
surgery was not associated with a lower risk of AKI defined by 
a doubling of serum creatinine or dialysis, {RR 1.09 [95% 
confidence interval (CI) 0.44–2.70]}, similarly to Billing et al.’s 
observations (18,21). Nevertheless, the continuing statin 
group showed a lower elevation of AKI biomarkers when 
compared to patients who interrupted statin assumption: 
IL-18 [RR 0.34 (95% CI, 0.18–0.62)], uNGAL [RR 0.41 (95% 
CI, 0.22–0.76)], uKIM-1 [RR 0.37 (95% CI, 0.20–0.76)], 
and pNGAL [RR 0.62 (95% CI, 0.39–0.98)]. Molnar et al.’s 
study poses the basis for a pre-AKI syndrome, and could 
finally suggest that: (I) statins should not be interrupted in 
patients chronically assuming them; (II) they may actually 
perform as anti-inflammatory and endothelial sparing 
agents in CSA-AKI; (III) AKI criteria, due to their intrinsic 
inability to accurately diagnose AKI in its early stages, could 
be inadequate to select patients that may benefit from specific 
therapeutic approaches or procedures; (IV) biomarkers could 
provide new means with higher sensitivity to identify these 
patients. Similarly to Molnar et al.’s study, Kruger et al. 
evaluated in a Phase II, multicenter, prospective, randomized, 
double-blind, placebo-controlled trial plasma IL-6 
concentration in a cohort of 250 critically ill patients with 
severe sepsis (123 receiving atorvastatin 20 mg daily vs. 127 
placebo). Statin therapy did not affect IL-6 levels (survival, 
length of stay, SOFA score, or C-reactive protein 
concentration), but prior statin users had a lower baseline 
IL-6 concentration in comparison with de novo statin 
therapy; importantly, the continuation of atorvastatin in 
such patients was associated with improved 28-day 
survival (26). Probably, multi-centre randomized controlled 
trials combining “classic” AKI criteria with new, more 
sensitive, markers are needed to better select patients, 
investigate drugs, and deliver future recommendations. In 
particular it is possible that a different selection of enrolled 
patients may be encouraged: novel diagnostic tools should 
be applied to improve stratification of candidate subjects 
and allow administration of nephro-protective drugs (and 
procedures) to those patients who actually have a chance to 
be “protected”. Furthermore the increased granularity of 
renal follow up in AKS or, more generically, “high risk” 
patients,  potential ly achieved through systematic 
biomarkers dosing, may also lead to a better understanding 
of renal pathophysiology, disease processes and treatment 
effects. As a final comment, it should be remarked that 
CSA-AKI is a multifactorial syndrome that needs a multi-
modal strategy to limit its occurrence and severity: even if 
single procedural strategies [e.g., off-pump technique (10) 
or remote ischemic preconditioning (27)] and isolated 
pharmacological  approaches [e.g. ,  stat ins (21) or 
fenoldopam (28)] have nowadays failed to prove definitive 
benefit, a combined approach, applying multiple therapies 
to specifically selected patients, has yet to be attempted.
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In conclusion, based on recent high level evidence, statins 
should not be started before cardiac surgery in patients not 
chronically taking them for AKI prevention being useless or 
potentially harmful. Possibly, patients already receiving them 
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